Elliott 1992.

Study characteristics
Methods	Randomised, double‐blind, cross‐over trial. Duration: 4 weeks for each treatment arm with a 2‐week run‐in period. Single‐centre trial in New Zealand. Home setting.
Participants	30 children previously diagnosed with CF using clinical and laboratory data. Age: median 10.1 years. Gender split: 17 girls, 13 boys.
Interventions	Group 1: Creon® (lipase 8000 BP, amylase 9000 BP, protease 210 BP). Group 2: Pancrease® (lipase 5000 BP, amylase 3000 BP, protease 350 BP). Participants were started on doses of lipase slightly lower or equivalent to pretrial period. Later they were allowed to adjust according to their requirement.
Outcomes	Mean weight gain, adequate daily intake of energy, fat and nitrogen, stool weight, FFE and nitrogen excretion.
Notes	For the outcomes of interest to the review, the results were given in a descriptive method; means and SDs not given.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Information not given.
Allocation concealment (selection bias)	Unclear risk	Information not given.
Blinding of participants and personnel (performance bias) Participants	Low risk	Both formulations were prepared in identical opaque capsules from commercial stock.
Blinding of participants and personnel (performance bias) Clinicians	Unclear risk	Information not given.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Information not given.
Incomplete outcome data (attrition bias) All outcomes	Low risk	2 participants withdrew consent and 1 participant was hospitalised due to respiratory exacerbations during the run‐in period.
Selective reporting (reporting bias)	High risk	Results were reported in a narrative method and could not be included in analysis
Other bias	High risk	Boehringer Ingelheim (NZ) Limited Kali Chemie provided funding and trial materials.